136 related articles for article (PubMed ID: 38340329)
1. Effects of the Cortisol Milieu on Tumor-Infiltrating Immune Cells in Corticotroph Tumors.
Kanzawa M; Shichi H; Kanie K; Yamamoto M; Yamamoto N; Tsujimoto Y; Bando H; Iguchi G; Kitano S; Inoshita N; Yamada S; Ogawa W; Itoh T; Fukuoka H
Endocrinology; 2024 Feb; 165(4):. PubMed ID: 38340329
[TBL] [Abstract][Full Text] [Related]
2. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.
Dai C; Liang S; Sun B; Kang J
Front Endocrinol (Lausanne); 2020; 11():608422. PubMed ID: 33362722
[TBL] [Abstract][Full Text] [Related]
3. Aggressive Cushing's Disease: Molecular Pathology and Its Therapeutic Approach.
Yamamoto M; Nakao T; Ogawa W; Fukuoka H
Front Endocrinol (Lausanne); 2021; 12():650791. PubMed ID: 34220707
[TBL] [Abstract][Full Text] [Related]
4. Clinical, Biological, Radiological Pathological and Immediate Post-Operative Remission of Sparsely and Densely Granulated Corticotroph Pituitary Tumors: A Retrospective Study of a Cohort of 277 Patients With Cushing's Disease.
Rak B; Maksymowicz M; Pękul M; Zieliński G
Front Endocrinol (Lausanne); 2021; 12():672178. PubMed ID: 34135861
[TBL] [Abstract][Full Text] [Related]
5. Low expression of the cell cycle inhibitor p27Kip1 in normal corticotroph cells, corticotroph tumors, and malignant pituitary tumors.
Lidhar K; Korbonits M; Jordan S; Khalimova Z; Kaltsas G; Lu X; Clayton RN; Jenkins PJ; Monson JP; Besser GM; Lowe DG; Grossman AB
J Clin Endocrinol Metab; 1999 Oct; 84(10):3823-30. PubMed ID: 10523037
[TBL] [Abstract][Full Text] [Related]
6. The expression of glucocorticoid and mineralocorticoid receptors in pituitary tumors causing Cushing's disease and silent corticotroph tumors.
Kober P; Rusetska N; Mossakowska BJ; Maksymowicz M; Pękul M; Zieliński G; Styk A; Kunicki J; Działach Ł; Witek P; Bujko M
Front Endocrinol (Lausanne); 2023; 14():1124646. PubMed ID: 37065760
[TBL] [Abstract][Full Text] [Related]
7. Cushing's disease due to a pituitary adenoma as a component of collision tumor: A case report and review of the literature.
Gezer E; Cantürk Z; Selek A; Çetinarslan B; Tarkun İ; Sözen M; Kiraz U; Gürbüz YS; Ceylan S; Çabuk B
J Med Case Rep; 2020 May; 14(1):59. PubMed ID: 32423480
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic correlations of silent corticotroph adenomas of the pituitary: report of four cases and literature review.
Sahli R; Christ ER; Seiler R; Kappeler A; Vajtai I
Pathol Res Pract; 2006; 202(6):457-64. PubMed ID: 16497445
[TBL] [Abstract][Full Text] [Related]
9. Preoperative normalization of cortisol levels in Cushing's disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists.
van der Pas R; Feelders RA; Gatto F; de Bruin C; Pereira AM; van Koetsveld PM; Sprij-Mooij DM; Waaijers AM; Dogan F; Schulz S; Kros JM; Lamberts SW; Hofland LJ
J Clin Endocrinol Metab; 2013 Dec; 98(12):E1880-90. PubMed ID: 24081741
[TBL] [Abstract][Full Text] [Related]
10. Silent corticogonadotroph adenomas: clinical and cellular characteristics and long-term outcomes.
Cooper O; Ben-Shlomo A; Bonert V; Bannykh S; Mirocha J; Melmed S
Horm Cancer; 2010 Apr; 1(2):80-92. PubMed ID: 20717480
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo.
Murasawa S; Kageyama K; Sugiyama A; Ishigame N; Niioka K; Suda T; Daimon M
Mol Cell Endocrinol; 2014 Aug; 394(1-2):37-46. PubMed ID: 25011056
[TBL] [Abstract][Full Text] [Related]
12. The Genomic Landscape of Corticotroph Tumors: From Silent Adenomas to ACTH-Secreting Carcinomas.
Andonegui-Elguera S; Silva-Román G; Peña-Martínez E; Taniguchi-Ponciano K; Vela-Patiño S; Remba-Shapiro I; Gómez-Apo E; Espinosa-de-Los-Monteros AL; Portocarrero-Ortiz LA; Guinto G; Moreno-Jimenez S; Chavez-Macias L; Saucedo R; Basurto-Acevedo L; Lopez-Felix B; Gonzalez-Torres C; Gaytan-Cervantes J; Ayala-Sumuano JT; Burak-Leipuner A; Marrero-Rodríguez D; Mercado M
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563252
[TBL] [Abstract][Full Text] [Related]
13. Integrative Clinical, Radiological, and Molecular Analysis for Predicting Remission and Recurrence of Cushing Disease.
Moreno-Moreno P; Ibáñez-Costa A; Venegas-Moreno E; Fuentes-Fayos AC; Alhambra-Expósito MR; Fajardo-Montañana C; García-Martínez A; Dios E; Vázquez-Borrego MC; Remón-Ruiz P; Cámara R; Lamas C; Carlos Padillo-Cuenca J; Solivera J; Cano DA; Gahete MD; Herrera-Martínez AD; Picó A; Soto-Moreno A; Gálvez-Moreno MÁ; Castaño JP; Luque RM
J Clin Endocrinol Metab; 2022 Jun; 107(7):e2938-e2951. PubMed ID: 35312002
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of corticotroph staining in radiosurgery for non-functioning pituitary adenomas: a multicenter study.
Cohen-Inbar O; Xu Z; Lee CC; Wu CC; Chytka T; Silva D; Sharma M; Radwan H; Grills IS; Nguyen B; Siddiqui Z; Mathieu D; Iorio-Morin C; Wolf A; Cifarelli CP; Cifarelli DT; Lunsford LD; Kondziolka D; Sheehan JP
J Neurooncol; 2017 Oct; 135(1):67-74. PubMed ID: 28913674
[TBL] [Abstract][Full Text] [Related]
15. A human ACTH-secreting corticotroph tumoroid model: Novel Human ACTH-Secreting Tumor Cell in vitro Model.
Zhang D; Hugo W; Redublo P; Miao H; Bergsneider M; Wang MB; Kim W; Yong WH; Heaney AP
EBioMedicine; 2021 Apr; 66():103294. PubMed ID: 33773184
[TBL] [Abstract][Full Text] [Related]
16. Immune Cell Infiltrates in Pituitary Adenomas: More Macrophages in Larger Adenomas and More T Cells in Growth Hormone Adenomas.
Lu JQ; Adam B; Jack AS; Lam A; Broad RW; Chik CL
Endocr Pathol; 2015 Sep; 26(3):263-72. PubMed ID: 26187094
[TBL] [Abstract][Full Text] [Related]
17. Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.
Liu NA; Araki T; Cuevas-Ramos D; Hong J; Ben-Shlomo A; Tone Y; Tone M; Melmed S
J Clin Endocrinol Metab; 2015 Jul; 100(7):2557-64. PubMed ID: 25942479
[TBL] [Abstract][Full Text] [Related]
18. USP8 and TP53 Drivers are Associated with CNV in a Corticotroph Adenoma Cohort Enriched for Aggressive Tumors.
Uzilov AV; Taik P; Cheesman KC; Javanmard P; Ying K; Roehnelt A; Wang H; Fink MY; Lau CY; Moe AS; Villar J; Bederson JB; Stewart AF; Donovan MJ; Mahajan M; Sebra R; Post KD; Chen R; Geer EB
J Clin Endocrinol Metab; 2021 Mar; 106(3):826-842. PubMed ID: 33221858
[TBL] [Abstract][Full Text] [Related]
19. Human pituitary corticotroph adenomas in vitro: morphologic and functional responses to corticotropin-releasing hormone and cortisol.
Horvath SE; Asa SL; Kovacs K; Adams LA; Singer W; Smyth HS
Neuroendocrinology; 1990 Mar; 51(3):241-8. PubMed ID: 2157992
[TBL] [Abstract][Full Text] [Related]
20. Silent corticotroph adenomas.
Karavitaki N; Ansorge O; Wass JA
Arq Bras Endocrinol Metabol; 2007 Nov; 51(8):1314-8. PubMed ID: 18209869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
